SCDM s CODE OF ETHICS FOR MARKETING MEDICAL DEVICES

Similar documents
CODE OF ETHICS CHAMBER OF MEDICAL DEVICES AND HEALTHCARE SUPPLIES N AT I O N AL AS S O C I AT I O N O F CO L O M B I AN B U S I N E S S M E N INDEX

International Health Care Business Integrity for Third Party Intermediaries

Code of Ethical Business Practice

Methodology for Compliance with the Research-Based Pharmaceutical Industry (LIF) Disclosure Code

Methodology for Compliance with the ABPI Disclosure Code. Introduction Page 1. General Comments Page 2. Indirect Transfers of Value Page 3

HCP CODE: GLOBAL CODE ON INTERACTIONS WITH HEALTHCARE PROFESSIONALS

Code on Global Interactions. with Healthcare Professionals

Prevention Of Corruption

Association of British Healthcare Industries Code of Ethical Business Practice

Glossary of Definitions

APPLICATION REGULATIONS OF THE CODE OF PRACTICE ON THE PROMOTION OF MEDICINAL PRODUCTS

University of Mississippi Medical Center Interactions with Industry Representatives

Code of Conduct Q&A Questions and Answers (version3) Medicines for Europe. Follow us on

MedTech Europe Code of Ethical Business Practice. December 2015

CODE OF CONDUCT. Medicines for Europe. Follow us on

Industry Funding of Continuing Medical Education

Insider Activities Policy

UNIVERSAL AVIONICS SYSTEMS CORPORATION Anti-Bribery Compliance Policy

Gifts to Referral Sources. Kim C. Stanger (11-17)

ANTI-CORRUPTION POLICY

ADP Anti-Bribery Policy Frequently Asked Questions

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2016 New Methodological Note

Any healthcare professional and healthcare organisation whose primary practice, principal professional address or place of incorporation

Any healthcare professional and healthcare organization whose primary practice, principal professional address or place of incorporation

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Anti-Corruption Policy

GIFTS, GRATUITIES AND BUSINESS COURTESIES

Balt USA, LLC Anticorruption Policy

2017 All rights reserved Elbit Systems Anti-Bribery Compliance Policy

SCIENCE CARE, INC. ANTI-BRIBERY POLICY

Foreign Corrupt Practices Act Policy

GLOBAL BUSINESS COURTESIES POLICY

POLICY: Number: Adopted: 3/28/79 Revised: 06/04/15 Last Review: 06/04/15. Group Health Cooperative Board of Trustees

HONORARIA POLICY AND PROCEDURE

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Travel & Expense Policy

SCOPE This policy applies to all operations of Mack Trucks, Inc., Volvo Group North America, LLC. and their divisions (the Corporation ).

Code of Ethics. The following policies are provided specifically to support the Company s high expectations of honesty, integrity and service.

Code of Conduct Medical Devices

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Foreign Corrupt Practices Act Policy

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

GLOBAL ANTI-BRIBERY COMPLIANCE POLICY

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2017 New Methodological Note

DOLBY LABORATORIES, INC. ANTICORRUPTION POLICY. (July 23, 2013)

Frequently Asked Questions

GLOBAL ANTI-CORRUPTION POLICY

FINANCIAL CONFLICT OF INTEREST POLICY

POLICY OF ETHICAL STANDARDS FOR BUSINESS CONDUCT

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Pfizer 2016 Disclosure Code Transparency Report

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

MacLean-Fogg Company Anti-Corruption Policy

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Dear NETGEARians, Thank you for helping NETGEAR achieve these important goals. Sincerely, Patrick

Anti-Bribery. Statement of Policy

FAIS CONFLICT OF INTEREST (COI) MANAGEMENT POLICY

GLOBAL ANTI-CORRUPTION POLICY

Island Health Guidelines for Commercial Support of Continuing Medical Education/Continuing Professional Development Activities

Understanding the Forces Driving Disclosure

EFPIA HCP/HCO DISCLOSURE CODE

CONDUCTING BUSINESS WITH CVS HEALTH

SIGMA ELECTRIC MANUFACTURING CORPORATION PVT LTD. ETHICS POLICY

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Ethics and Code of Conduct Policy. Adopted April 22, 2011

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Novartis Methodological Note

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

The JAMS COI Management Guidance on Eligibility Criteria for Clinical Practice Guideline Formulation March, 2017

RESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY

Document Type Doc ID Status Version Page/Pages. Policy LDMS_001_ Effective of 11 Title: Global Policy on Ethical Interactions

ANTI-BRIBERY CODE. September 2017

Novartis Methodological Note

MTI WIRELESS EDGE LTD - Anti-Bribery Compliance Policy

NASPGHAN Mission Statement.

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Novartis Methodological Note

KLA CORPORATION. Our policy is: KLA expressly prohibits any company director, officer, employee or business partner from directly or indirectly:

FOREIGN CORRUPT PRACTICES POLICY

Risk Management and Compliance

NEXTERA ENERGY, INC.

Employees may incur and/or submit for reimbursement only those business expenses that are consistent with Cardinal Health policy.

Legal Policy. Anti-Corruption Policy and Compliance Manual

AstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Siemens Compliance Guide Anti-Corruption

FOREIGN CORRUPT PRACTICES ACT COMPLIANCE POLICY

AIFP CODE ON DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS

NTI-BRIBERY CORRUPTION OLICY

TAX ENGAGEMENT LETTER

Anti-Corruption and Healthcare Compliance Policy. Approved By: Corporate Compliance Effective Date: October 15, 2015

Novartis Methodological Note

Business Ethics: Code of Conduct

Sanofi-Aventis Bulgaria EOOD Methodological Note

Korea Compliance Update Asia Pacific Pharmaceutical Compliance Congress Mini Summit XIII SEPTEMBER 17, 2014

Anti-Bribery and Corruption Policy

The following are common situations where the acquisition of property by a charitable organization is not subject to sales tax.

FRAUD AND ABUSE LAW IMPLICATED BY COMPENSATION ARRANGEMENTS. Lee Rosebush, PharmD, RPh, MBA, JD

Code of Conduct Medical Devices

ANTI-BRIBERY AND ANTI-CORRUPTION POLICY

TAX ENGAGEMENT LETTER

Transcription:

Scientific Society Medical Device Industry SCDM s CODE OF ETHICS FOR MARKETING MEDICAL DEVICES 1. INTRODUCTION It is necessary that the marketing of medical devices be governed by ethical standards that guarantee any purchasing decision, which shall always be based on fundamental attributes such as Quality, Safety and Effectiveness. These principles shall ensure that patients are the most important factor in a decision to purchase any device, and any violation of these principles shall affect the credibility and trustworthiness of anyone displaying such conduct. Ethical interactions between medical device marketing Companies and Healthcare Institutions are important for implementing new products and Technologies and promoting innovation, while basically providing for respect for patients. Any ethical interaction between medical device marketing Companies and Healthcare Institutions shall be based on the following five fundamental Principles: Integrity. This means honest, sincere and fair relationships with all of the parties. Independence. This means that the interactions of Healthcare Professionals ( PS ) with Companies should not bias a medical decision in the best interest of the patient. Pertinence. This means that agreements are made in accordance with appropriate business standards, and they are exact as well as exempt from corrupt purposes.

Transparency. This means that companies and Healthcare Professionals are open in terms of significant financial relationships between the parties. Furtherance. This means that relationships are aimed at making advances in medical technology, innovation and patient care. Interactions between medical device marketing companies and Healthcare Institutions must also abide by the following additional Principles: 1. Cooperative interactions between companies and healthcare professionals are to maintain independent decision-making on the part of healthcare professionals and guarantee public trust in the integrity with which products are selected, treatment and the different types of care afforded to patients to the extent that: The agreement is to meet a legitimate business need or be responsive to a legitimate interest of the Company, and payments under the agreement are not to be contingent upon any purchases or prescriptions of products, and they are to be consistent with the fair market value. Whenever interactions are in connection with rendition of services, these should be rendered by such persons or entities which have training whose evidence may be provided, experience, know-how or the ability to render services. 2. Consulting contracts between companies and healthcare professionals should fund research and development for making advances in medical science, new technological development, current product and service optimization and better quality and efficiency in patient care. Consulting contracts are not to be used as a means for securing inappropriate incentives. Inappropriate incentive means any remunerated arrangement for the purpose of obtaining any inappropriate influence in the medical decision on selecting a product. Contracts are to include comprehensive compensation agreements with the healthcare professional or institution; that is to say, all payments by way of fees, royalties and benefits, including any product and advertising samples whenever these are required. 3. Financial support of companies for educating healthcare professionals, for instance, by way of support for third-level educational programs and educational grants, are to protect independent medical education, and they should not be used as a means to gain inappropriate incentives. 1.- Such financial support: May be allocated to specific educational activities and not to promotional purposes. May not include any product use or act as hidden discounts 1

2 Conference invitations made to healthcare professionals for professional or educational purposes in the medical field are not to be contingent upon any obligation to prescribe or purchase any products. 2.- Locations where conferences and symposia take place are to be adequate for and ancillary to the main purpose of the event. 3.- No financial support shall be provided to non-educational activities, such as sporting and artistic events. 4. Companies may deliver training to healthcare professionals in a specific medical device and its use and application to facilitate the safe and effective use of medical technologies. Training is understood as a demonstration targeting a healthcare professional on the safe and effective use of a medical device. These training sessions include training sessions in new products or a specific use or training for updating. 5, Companies are not to provide any entertainment and recreation to healthcare professionals as inappropriate incentives. Any attendance to entertainment events, consent or agreement to receive any gift, commission or gratuity is to be deemed inappropriate for fostering appropriate business relationships. 6. Meals, Trips, Lodging. These expenses incurred when attending conferences or symposia or due to expenses related to a service payment arrangement are to be at adequate rates; they are not to include any luxury hotels, resorts, high-priced meals, entertainment, recreation and any expenses incurred by healthcare professionals for companions or spouses. 7. Company donations to charity or other philanthropic purposes should fund well-known (bona fide) charity organizations and missions, and they should not be a means to benefit any healthcare professional in particular or used as a marketing tool in terms of specific transactions with customers; they are to be made in a consistent manner and documented adequately in accordance with the following provisions: a) Donations shall be used by Organizations pursuant to current law. b) No donation shall bind any Organization to purchase, use, recommend or arrange for the use of any product of the donor Company. c) None of the parties is to make any payment or offer or transfer any valuable to any government official [or] employee, any political official or candidate to public office or any other third party related to a transaction in such a way as to deem that it is corrupt in accordance with the Law on Transparency of the State.

3

8. Free products are not to be used as a means for inappropriate incentivisation. Nevertheless, companies may provide healthcare professionals with reasonable amounts of products for purposes of evaluation and demonstration. Occasional presents may be given to healthcare professionals; these are to have a scientific educational value, and they should not have the motivation to exercise any inadequate influence or gain reciprocity; further, their cost should be reasonable, and they should be consistent with circumstances. 9. Educational Grants are to be given solely to obtain more information on the safety and performance of a medical device and not as a means to promote a product or influence the decision on purchasing or prescribing products; these are to be evaluated on the basis of objective criteria, and they shall always be intended for supporting independent research. 10. Management and financial specifics are to be determined by way of an agreement in writing, and any compensation is to be consistent with the fair market value assigned to these activities. These grants are not to be approved or managed by any business division of the Companies marketing or sales divisions, and they shall be intended to add value to the scientific and clinical development of healthcare professionals in benefit of their patients. 11. Companies are to support this code of ethics: a) By way of senior reliable executive who observes this code. b) By drafting an educational guide for enabling compliance with this code of ethics. c) By training the staff to have them duly comply with this code of ethics. d) By drafting an Ethics Handbook for providing for due compliance. e) By creating the appropriate communication channels to enable any employee to give his opinion on topics involving business ethics. f) By making sure that anyone involved in the product distribution chain is able to give his opinion whenever there is any doubt. g) By making sure that any third party on the distribution chain becomes part of this code of ethics. Nov. 26, 2013 4